会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Methods of Treating Kawasaki Disease using IL-1beta Antibodies
    • 使用IL-1beta抗体治疗川崎病的方法
    • US20160002328A1
    • 2016-01-07
    • US14861191
    • 2015-09-22
    • Hermann GramThomas Jung
    • Hermann GramThomas Jung
    • C07K16/24
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及IL-1和bIG - 配体/ IL-1受体破坏化合物(本文中称为“IL-1β化合物”)的新用途。 例如破坏IL-1b配体-IL-1受体相互作用的小分子化合物,IL-1b抗体或IL-1受体抗体。 本文所述的IL-1b结合分子,例如 本文公开的抗体,例如 IL-1b结合化合物或IL-1受体结合化合物,和/或降低IL-1b配体或IL-1受体蛋白水平的RNA化合物,用于治疗和/或预防自身炎症综合征。 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。
    • 5. 发明申请
    • Methods of Using IL-1beta Compounds
    • 使用IL-1β化合物的方法
    • US20150322148A1
    • 2015-11-12
    • US14810556
    • 2015-07-28
    • Philip LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • Philip LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • C07K16/24
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/56C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物(本文中称为“IL-1β化合物”)的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用,IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体,例如 IL-1和bgr 结合化合物或IL-1受体结合化合物,和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平,用于治疗和/或预防自身炎症综合征,例如, 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,哺乳动物,特别是人类。
    • 8. 发明申请
    • Novel Use of IL-1beta Compounds
    • IL-1β化合物的新用途
    • US20120039910A1
    • 2012-02-16
    • US13283165
    • 2011-10-27
    • Phil LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • Phil LoweHermann GramThomas JungTimothy WrightTrevor Mundel
    • A61K39/395A61P37/02
    • C07K16/245A61K39/3955A61K2039/505C07K2317/21C07K2317/56C07K2317/565C07K2317/76C07K2317/92
    • This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
    • 本发明涉及使用IL-1和配体/ IL-1受体破坏性化合物(本文中称为“IL-1β化合物”)的方法; 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用,IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 如本文所述的结合分子。 本文公开的抗体,例如 IL-1和bgr 结合化合物或IL-1受体结合化合物,和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平,用于治疗和/或预防自身炎症综合征,例如, 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法,例如, 少年类风湿关节炎或成人类风湿关节炎综合征,在哺乳动物,特别是人类。